Drugs Health Pharma

Johnson & Johnson to buy Proteologix Inc., for $850 million in cash

HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.

Read More
Drugs Health Pharma

Johnson & Johnson’s blood cancer medicine cleared for bi-weekly use

HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.

Read More
Drugs Health Pharma

FDA probing T cell cancer therapies of Gilead Sciences, Novartis, J & J

HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.

Read More
Health Medical Pharma

J&J to file USFDA request to start trials for surgical robots

Johnson & Johnson will apply with the USFDA to start clinical trials in the second half of 2024 for its robotic surgical system.

Read More
Drugs Health Pharma

GSK to pay $1 billion to acquire exclusive rights for J&J hepatitis B therapy

 HQ Team November 1, 2023: GSK, a British pharmaceutical company, will pay $1 billion to Johnson & Johnson for transferring exclusive global rights.

Read More
Drugs Health Pharma

J&J halts final phase of trials of a drug to treat hypertension, says “futile” 

HQ Team September 7, 2023: Johnson & Johnson has decided to halt an experimental trial, in its final stages, on a drug to.

Read More
Drugs Pharma

Johnson & Johnson pulls out of HIV phase III trial

Johnson & Johnson stopped the phase III trial of its global HIV vaccine trial after it found that the regimen was ineffective in.

Read More
Medical

Hetero buys J&J’s manufacturing site in India

HQ Team October 18, 2022: Hetero, an Indian pharmaceutical company, announced the acquisition of a brownfield manufacturing plant of Johnson & Johnson Private.

Read More
X